Co-Trimoxazole
drugOn this page
Also known as cotrimoxazole
Summary
Co-Trimoxazole (CHEMBL58061) is a phase-3 clinical-stage small molecule; indicated across 7 conditions including bacterial infectious disease and infectious peritonitis.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 7 conditions
- Clinical trials: 25
- Chemistry: 543.6 Da · C24H29N7O6S
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL58061 |
| Name | Co-Trimoxazole |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 358641 |
| Molecular formula | C24H29N7O6S |
| Molecular weight | 543.6 |
| InChIKey | WZRJTRPJURQBRM-UHFFFAOYSA-N |
SMILES: CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N.COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N
IUPAC name: 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine
Also known as: Co-trimoxazole, Co-Trimoxazole, cotrimoxazole, COTRIMOXAZOLE, CO-TRIMOXAZOLE
Patent coverage: 1,032 distinct patent families (2,268 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| bacterial infectious disease | 3 | MONDO:0005113 | EFO:0000771 |
| infectious peritonitis | 3 | MONDO:0004522 | EFO:0008588 |
| severe acute respiratory syndrome | 2 | MONDO:0005091 | MONDO:0100096 |
| tuberculosis | 2 | MONDO:0018076 | MONDO:0018076 |
| pneumocystosis | 2 | MONDO:0019121 | EFO:0007448 |
| lung disorder | 2 | MONDO:0005275 | EFO:0003818 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 25.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 10 |
| PHASE2 | 6 |
| PHASE4 | 5 |
| PHASE2/PHASE3 | 2 |
| Not specified | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00674921 | PHASE4 | UNKNOWN | Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda |
| NCT01086878 | PHASE4 | COMPLETED | Safety of Cotrimoxazole in HIV- and HAART-exposed Infants |
| NCT01420341 | PHASE4 | COMPLETED | Co-trimoxazole as Maintenance Therapy for Melioidosis |
| NCT03087890 | PHASE4 | COMPLETED | Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria |
| NCT03187834 | PHASE4 | COMPLETED | Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso |
| NCT04310930 | PHASE2/PHASE3 | RECRUITING | Finding the Optimal Regimen for Mycobacterium Abscessus Treatment |
| NCT05696093 | PHASE3 | RECRUITING | Efficacy of Cotrimoxazole as a De-escalation Treatment of Ventilator-Associated Pneumonia in Intensive Care Unit |
| NCT00330304 | PHASE3 | COMPLETED | Isoniazid Prophylaxis With Concomitant Cotrimoxazole in HIV-infected Children |
| NCT00396526 | PHASE3 | COMPLETED | ICMR-Indiaclen Trial on Amoxycillin vs Cotrimoxazole for Non-Severe Pneumonia |
| NCT00427076 | PHASE3 | COMPLETED | Cotrimoxazole Versus Vancomycin for Invasive Methicillin-resistant Staphylococcus Aureus Infections |
| NCT00711906 | PHASE3 | TERMINATED | Daily Co-trimoxazole Prophylaxis to Prevent Malaria in Pregnancy |
| NCT00933049 | PHASE3 | COMPLETED | Cotrimoxazole Versus Amoxicillin in the Treatment of Community Acquired Pneumonia in Children Aged 2-59 Months |
| NCT00970879 | PHASE3 | COMPLETED | Prevention of Pregnancy-associated Malaria in HIV-infected Women: Cotrimoxazole Prophylaxis Versus Mefloquine |
| NCT01053325 | PHASE3 | COMPLETED | Establishing Effectiveness of Daily Co-trimoxazole Prophylaxis For Prevention of Malaria in Pregnancy |
| NCT01777737 | PHASE3 | TERMINATED | Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole |
| NCT02773407 | PHASE3 | COMPLETED | Nepal Undifferentiated Febrile Illness Trial |
| NCT04884490 | PHASE2/PHASE3 | COMPLETED | The Role of High Dose Co-trimoxazole in Severe Covid-19 Patients |
| NCT05835479 | PHASE2 | RECRUITING | Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults |
| NCT01229761 | PHASE2 | COMPLETED | Study to Improve Survival Among HIV-Exposed Infants in Botswana |
| NCT01701297 | PHASE2 | TERMINATED | VSL#3 and Spontaneous Bacterial Peritonitis |
| NCT01832987 | PHASE2 | COMPLETED | Pharmacokinetic Parameters of Co-trimoxazole |
| NCT04470531 | PHASE2 | UNKNOWN | Role of Co-trimoxazole in Severe COVID-19 Patients |
| NCT04985110 | PHASE2 | UNKNOWN | Administration of Antibiotic Prophylaxis for Transperineal Prostate Biopsy in Cipto Mangunkusumo Hospital |
| NCT00187070 | Not specified | COMPLETED | Large Cell Lymphoma Pilot Study III |
| NCT00355602 | Not specified | COMPLETED | Antibiotics for the Treatment of Ulcerative Colitis |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
PharmGKB dosing guidelines (1) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):
| Guideline | Source | Gene(s) | Dosing | Recommendation |
|---|---|---|---|---|
| Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, | CPIC | G6PD |
PharmGKB also curates 9 clinical and 58 variant annotation(s) for this drug (gene-keyed; see PharmGKB).
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).